

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 7/08, 7/06, G01N 33/50, A61K</b> <b>47/48 // G01N 33/94</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/39155</b>
			<b>(43) International Publication Date:</b> 6 July 2000 (06.07.00)
<b>(21) International Application Number:</b> PCT/EP99/10378 <b>(22) International Filing Date:</b> 23 December 1999 (23.12.99) <b>(30) Priority Data:</b> 98124591.3 23 December 1998 (23.12.98) EP <b>(71) Applicant (for all designated States except US):</b> MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstrasse 8, D-80539 München (DE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PADOVAN, Elisabetta [IT/CH]; Hammerstrasse 115, CH-4057 Basel (CH). WELTZIEN, Hans, Ulrich [DE/DE]; Schillhof 5, D-79110 Freiburg (DE). <b>(74) Agents:</b> WEICKMANN, H. et al.; Kopernikusstrasse 9, D-81679 München (DE).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> PENICILLINS AS PHARMACEUTICALS FOR THE DOWNREGULATION OF IFN $\gamma$ PRODUCTION			
<b>(57) Abstract</b>  According to the present invention, penicillins are used for the production of a pharmaceutical for therapeutic use in autoimmune diseases or other pathological situations where IFN $\gamma$ -mediated effects are involved in the progression of the disease. Another use of the invention relates to hapten-modified peptides for the production of a pharmaceutical for therapeutic use in autoimmune diseases or other pathological situations where IFN $\gamma$ mediated effects are involved in the progression of the disease.			